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 Severe Acute Respiratory Syndrome 
Coronavirus-2 (SARS-CoV-2) that causes Corona 
Virus Disease -19 (COVID-19) is a novel virus and 
hence humans do not have any prior immunity to 
it.[1] Every human being is susceptible to this viral 
infection and rapid spread worldwide made WHO 
declare it as a global pandemic.[2]
 Cancer patients are even more vulnerable 
not only because they are immunocompromised by 
the disease process itself, but also due to potential 
effect of chemotherapy, radiotherapy along with 
substantial effect on their timing of treatment. 
Patients older than 65 years, and those with pre-
existing co-morbidities are considered more at 
risk.[3,4,5] Considering the increased chances of 
intensive care unit admission, need of mechanical 
ventilation and possible mortality, all cancer patients 
should be educated about preventive measures, 
personal protection, social distancing and isolation.
[6] Another possible impact of COVID-19 could 
be delays in initial evaluation, diagnosis and 
initiation of actual treatment which are independent 
risk factors for cancer related mortality.[6] This is 
due to limited services provided at the health care 
facilities, lockdown effects, fear of being infected 
and economic crisis.
 Implementation of preoperative screening 
for COVID-19 before initiating treatment for 
gynecologic cancer is still a debate. Most of the 
patients are asymptomatic and available Polymerase 
Chain Reaction (PCR) testing from naso-pharyngeal 
swab has false negative rate of around 30%.[7] In 
this pandemic, all cases can be considered positive 
unless proven otherwise and every possible 
precaution and protective measure should be taken 
in the operation theatre to protect the health care 
workers as well as other patients. PCR should be 
done at least a week prior to the surgery.[7] As 
false negative rate is high, checking for symptoms 
like fever, cough, tiredness, difficulty in breathing, 
sore throats or flu-like symptoms should be done 
at the time of admission and preventive and full 
protective measures should also be taken even if 
PCR is negative. Another recommendation for the 
PCR negative cases is to perform Low-dose chest 
computed tomography (LDCT) scan 48 hours before 
surgery for characteristic COVID-19 lung changes.
[7]
 There are many guidelines with alternative 
management options to help clinicians decide the 
management of gynecologic cancer during this 
pandemic.[8,9,10] European Society for Medical 
Oncology (ESMO) has prioritized patients as 
high priority, medium priority and low priority 
for outpatient visits, imaging, surgical oncology, 
medical oncology and for radiation oncology.[3,4,5]
This has been formulated considering emergency 
conditions associated with cancer patients, clinical 
or radiological stage, histological variant and grade, 
ongoing or scheduled chemotherapy or radiation, and 
patients on trials and palliative therapy. The details 
are made available in ESMO website for different 
gynecologic malignancies like ovarian, endometrial 
and cervical cancer.[3,4,5]
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 Patients with gynecologic malignancy 
should be triaged for observation or intervention. 
Basic principle is to prioritize intervention for 
oncologic emergencies and initiate treatment for 
aggressive or advanced stage disease and reasonably 
postpone intervention for benign or pre-invasive or 
early stage low grade malignancy after informed 
consent.[6] A simple categorization can be category 
1 or low acuity surgery that are not life threatening 
and can be postponed for few weeks or months.[6] 
This includes management of pre-invasive lesion of 
cervix or endometrium. Category 2 or intermediate 
acuity surgery includes those conditions that are not 
life threatening but with potential future morbidity 
or mortality.[6] Low risk cancer like early cervical 
cancer and well differentiated endometrial cancers 
with co-morbidities are some of the examples for 
which surgery can be postponed for reasonable 
period after informed decision making and in case 
surgery is done, they should be considered for early 
discharge post operatively.[6] Category 3 or high 
acuity surgery includes life threatening conditions 
like bowel obstruction, highly symptomatic patients, 
type II endometrial cancers, ovarian cancer, interval 
debulking surgery after 3–4 cycles of chemotherapy, 
uterine sarcoma, those in need of emergency 
procedures, excision of malignant recurrences and 
gestational trophoblastic neoplasm.[6] Surgery 
should not be postponed if COVID-19 census is low 
and resources permit. Only life saving procedure 
should be done when there is high burden of 
COVID-19 cases and with limited resource supply 
and rest should be closely observed. Selected cases 
should be subjected to neo-adjuvant therapy after 
informed consent.[6]
 When surgery is planned, laparoscopic 
procedures are preferably avoided.[6] After surgery 
also, Enhance Recovery After Surgery (ERAS) 
protocol may be implemented for rapid recovery, 
early discharge and to decrease chance of being 
infected.[11] The key components of ERAS protocol 
in the preoperative setting is to avoid mechanical 
bowel preparation, provide light meal up until 
six hours, and consume clear fluids including oral 
carbohydrate drinks up until two hours before 
initiation of anesthesia and encourage  use of pre-
medications (acetaminophen, non-steroidal anti-
inflammatory drugs, anti-emetics). Similarly, 
intraoperative measures include maintenance of 
normothermia and euvolemia, avoidance of surgical 
drains and nasogastric tubes and infiltration of wound 
with local anesthetic agents. Post-operative measures 
are to prevent nausea and vomiting using ≥2 anti-
emetics (multimodal approach), early introduction 
of solid diet post-operatively (day 0–1), multimodal 
narcotic-sparing post-operative analgesia (use 
of scheduled non-narcotic medications with oral 
narcotic medications only as needed), peripheral 
lock intravenous when patient has 600 ml oral intake, 
remove urinary catheter on post-operative day 
one in the absence of contraindications and active 
mobilization.[11] 
 Telemedicine is a useful tool for follow-
up of patients.[7] But it is limited by the inability 
to perform physical examination. Considering the 
COVID-19 pandemic, remote consultation should 
be preferred rather than face to face visits and patient 
should be called for evaluation based on reported 
symptoms.[7]
 In conclusion, every case of gynecologic 
malignancies needs to be considered as COVID-
19positive cases and adequate precautions should 
be taken. They should be triaged for immediate 
intervention or reasonably rescheduled for treatment 
after informed consent based on their clinical profile.
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